Oncology MRI

Catch up on the top AI-related news and research in radiology over the past month.

In a study of 351 women with BI-RADS 3-5 non-mass enhancement breast lesions, researchers found that multiparametric MRI offered 98.4 percent sensitivity and a 97.9 percent negative predictive value (NPV).

Catch up on a variety of new FDA clearances in radiology from the past week.

In a new meta-analysis examining the impact of MRI-based AI models for predicting high-grade hepatocellular carcinoma, researchers noted a 10 percent decline in AUC between internal validation and external validation.

The combination of sustained high-gradient performance and AI capabilities with the Titanion MR may facilitate the use of imaging biomarkers that provide insight into tissue microstructure

Cystadenomas and cystadenofibromas accounted for 46 percent of benign lesions initially scored as O-RADS 4 and 5 lesions on pelvic ultrasound, according to newly published research.

In a recent interview with Diagnostic Imaging, Soroush Adam Ramin, MD, discussed the enhanced 3D visualization and prognostic capability of Unfold AI, an MRI-based software platform that was recently added to Medicare Physician Fee Schedules for the West Coast and Mountain West regions.

In a recent interview with Diagnostic Imaging, Wendie Berg, MD, PhD, shared her perspective on various aspects of the controversial breast cancer screening guidance issued by the American College of Physicians (ACP), including the use of supplemental imaging in women with dense breasts.

Patients with PRECISE 4 or 5 scores based on prostate MRI had over a 4.5-fold higher likelihood of biopsy progression in comparison to those with PRECISE 1-3 scores, according to a new multicenter study involving over 1,600 patients.

In a roundup of breast imaging news and research from April 2026, we take a look back at pertinent findings with AI and digital breast tomosynthesis (DBT), breast MRI studies and breast cancer screening guidelines from the National Comprehensive Cancer Network (NCCN) and the American College of Physicians (ACP).

Providing enhanced multidimensional displays of MRI and CT imaging, the Avatar Medical Vision software may facilitate improved surgical planning and intraoperative communication.

Catch up on the most-well viewed radiology content in April 2026.

Catch up on the top radiology content of the past week.

Catch up on a variety of new FDA clearances in radiology from the past week.

Employing the SwiftMR software with deep learning reconstruction solutions from original equipment manufacturers (OEMs) may provide additional sequence coverage as well as scan time reduction.

Catch up on the top radiology content of the past week.

In a time-independent test set from a new retrospective study, gadoxetic-acid enhanced MRI provided nearly 38 percent higher sensitivity for detecting sub-centimeter hepatocellular carcinoma recurrence (HCC) in contrast to extracellular contrast agent-enhanced MRI.

For patients with cardiac dysfunction related to neoadjuvant chemotherapy for invasive breast cancer, new MRI research shows increased risks for concurrent decreases in total brain volume and white matter volume.

There was no statistically significant difference in sensitivity rates for lesion detection between breast MRI scans with minimum or mild background parenchymal enhancement (BPE) and those with moderate or marked BPE, according to a newly published study involving over 300 women.

A combination of time-dependent diffusion MRI-derived parameters and quantitative macromolecular proton fraction (MPF) demonstrated a 96 percent AUC for differentiating high-grade and low-grade cervical cancer, according to newly published research.

Catch up on the top radiology content of the past week.

Use of an MRI-based deep learning model also led to a greater than 33 percent increase in detecting brain metastases less than or equal to 3 mm, according to newly published research.

Catch up on the top radiology content of the past week.

The MRI-based Early Recurrence Individualized Score (MERIS) demonstrated an 18 percent higher C-index than the Barcelona Clinic Liver Cancer (BCLC) staging system for predicting early recurrence of hepatocellular carcinoma (HCC) for patients who had resection of solitary HCC tumors.